

Davide Corti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5170634/davide-corti-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121
papers

12,649
citations

55
h-index

112
g-index

129
ext. papers

19,719
ext. citations

27.5
avg, IF

6.53
L-index

#	Paper	IF	Citations
121	Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. 2022,		2
120	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.. <i>Cell</i> , 2022,	56.2	21
119	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.. <i>Science</i> , 2022 , 375, eabm8143	33.3	23
118	Predicting the mutational drivers of future SARS-CoV-2 variants of concern.. <i>Science Translational Medicine</i> , 2022 , 14, eabk3445	17.5	9
117	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.. <i>Nature Medicine</i> , 2022,	50.5	102
116	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity.. <i>Nature</i> , 2022,	50.4	95
115	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.. <i>PLoS ONE</i> , 2022 , 17, e0263328	3.7	2
114	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.. <i>PLoS Pathogens</i> , 2022 , 18, e1010248	7.6	7
113	Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy.. <i>Current Opinion in Virology</i> , 2022 , 53, 101204	7.5	0
112	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.. <i>Science</i> , 2022 , 375, eabn8652	33.3	71
111	Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. 2022,		3
110	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.. <i>Nature</i> , 2021,	50.4	204
109	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. 2021,		16
108	SARS-CoV-2 spike conformation determines plasma neutralizing activity. 2021,		6
107	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021 , eabl85063.3	33.3	65
106	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. 2021,		22
105	Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	3

104	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry 2021 ,		7
103	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy 2021 ,		5
102	Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020 2021 ,		142
101	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021 , 27, 717-726	50.5	497
100	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021 , 184, 1171-1187.e20	56.2	331
99	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , 2021 , 593, 136-141	50.4	376
98	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains 2021 ,		2
97	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021 , 184, 2332-2347.e16	56.2	316
96	SARS-CoV-2 immune evasion by variant B.1.427/B.1.429 2021 ,		62
95	Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody 2021 ,		14
94	Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape 2021 ,		12
93	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021 , 596, 103-108	50.4	91
92	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. <i>Cell Reports</i> , 2021 , 35, 109292	10.6	172
91	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021 , 184, 3086-3108	56.2	108
90	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , 2021 , 595, 707-712	50.4	168
89	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021 , 373, 648-654	33.3	197
88	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 2021 ,		34
87	SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies 2021 ,		39

86	Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. <i>Lancet Regional Health - Europe, The</i> , 2021 , 1, 100013		29
85	After the pandemic: perspectives on the future trajectory of COVID-19. <i>Nature</i> , 2021 , 596, 495-504	50.4	68
84	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021 , 597, 103-108	50.4	94
83	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021 , 597, 97-102	50.4	118
82	Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants 2021 ,		31
81	Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection. <i>Angewandte Chemie</i> , 2021 , 133, 21381-21385	3.6	1
80	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , 2021 , 598, 342-347	50.4	63
79	Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection. <i>Angewandte Chemie - International Edition</i> , 2021 , 60, 21211-21215	16.4	9
78	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021 , 599, 114-119	50.4	334
77	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021 , 184, 5432-5447.e16	56.2	34
76	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , 2021 , 373, 1109-1116	33.6	80
75	SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies 2021 ,		69
74	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. <i>Nature</i> , 2020 , 583, 290-304	30.4	1028
73	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020 , 28, 475-485.e5	23.4	252
72	Capsid protein structure in Zika virus reveals the flavivirus assembly process. <i>Nature Communications</i> , 2020 , 11, 895	17.4	43
71	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 2020 , 3606354	1	12
70	Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein. <i>Nature Communications</i> , 2020 , 11, 596	17.4	13
69	Structural and functional analysis of a potent sarbecovirus neutralizing antibody 2020 ,		42

68	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 2020 ,		10
67	Closing coronavirus spike glycoproteins by structure-guided design 2020 ,		7
66	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , 2020 , 183, 1024-1042.e21	56.2	601
65	AncesTree: An interactive immunoglobulin lineage tree visualizer. <i>PLoS Computational Biology</i> , 2020 , 16, e1007731	5	4
64	Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. <i>Nature</i> , 2020 , 588, 485-490	50.4	40
63	A combination of two human monoclonal antibodies cures symptomatic rabies. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12628	12	7
62	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. <i>Nature Structural and Molecular Biology</i> , 2020 , 27, 942-949	17.6	89
61	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. <i>Nature</i> , 2020 , 584, 353-363	30.4	289
60	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020 , 370, 950-957	33.3	314
59	AncesTree: An interactive immunoglobulin lineage tree visualizer 2020 , 16, e1007731		
58	AncesTree: An interactive immunoglobulin lineage tree visualizer 2020 , 16, e1007731		
57	AncesTree: An interactive immunoglobulin lineage tree visualizer 2020 , 16, e1007731		
56	AncesTree: An interactive immunoglobulin lineage tree visualizer 2020 , 16, e1007731		
55	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. <i>Antiviral Research</i> , 2019 , 163, 70-74	10.8	8
54	Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. <i>Cell</i> , 2019 , 176, 1026-1039.e15	56.2	416
53	Alternative conformations of a major antigenic site on RSV F. <i>PLoS Pathogens</i> , 2019 , 15, e1007944	7.6	15
52	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. <i>Cell Host and Microbe</i> , 2019 , 26, 623-637.e8	23.4	33
51	Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations. <i>Cell Host and Microbe</i> , 2019 , 25, 367-376.e5	23.4	47

50	Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	50
49	Therapeutic Administration of Broadly Neutralizing F16 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors. <i>Frontiers in Immunology</i> , 2018 , 9, 865	8.4	14
48	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 12265-12270	11.5	41
47	Influenza hemagglutinin membrane anchor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 10112-10117	11.5	61
46	Tackling influenza with broadly neutralizing antibodies. <i>Current Opinion in Virology</i> , 2017 , 24, 60-69	7.5	95
45	Protection of calves by a prefusion-stabilized bovine RSV F vaccine. <i>Npj Vaccines</i> , 2017 , 2, 7	9.5	27
44	A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. <i>Cell</i> , 2017 , 171, 229-241	16.15	85
43	Antibody-based assay discriminates Zika virus infection from other flaviviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 8384-8389	11.5	129
42	Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant <i>Klebsiella pneumoniae</i> . <i>Nature Communications</i> , 2017 , 8, 1991	17.4	37
41	Anti-LPS antibodies protect against <i>Klebsiella pneumoniae</i> by empowering neutrophil-mediated clearance without neutralizing TLR4. <i>JCI Insight</i> , 2017 , 2,	9.9	19
40	Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. <i>Science</i> , 2016 , 353, 823-6	33.3	528
39	Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. <i>Cell</i> , 2016 , 166, 596-608	56.2	228
38	Platelet-derived growth factor- β receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. <i>Nature Microbiology</i> , 2016 , 1, 16082	26.6	115
37	Antibody-guided vaccine design: identification of protective epitopes. <i>Current Opinion in Immunology</i> , 2016 , 41, 62-67	7.8	35
36	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , 2016 , 351, 1339-42	33.3	280
35	SARS-like WIV1-CoV poised for human emergence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 3048-53	11.5	279
34	A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. <i>Nature</i> , 2016 , 529, 105-109	50.4	105
33	Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. <i>EMBO Molecular Medicine</i> , 2016 , 8, 407-21	12	51

32	Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 9430-5	11.5	34
31	Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 10473-8	11.5	170
30	Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. <i>Nature Communications</i> , 2015 , 6, 7375	17.4	61
29	Rapid development of broadly influenza neutralizing antibodies through redundant mutations. <i>Nature</i> , 2014 , 516, 418-22	50.4	219
28	Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells. <i>Microbiology Spectrum</i> , 2014 , 2,	8.9	30
27	Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 17965-70	11.5	96
26	Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. <i>Nature</i> , 2013 , 501, 439-43	50.4	175
25	Broadly neutralizing antiviral antibodies. <i>Annual Review of Immunology</i> , 2013 , 31, 705-42	34.7	351
24	A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. <i>Science</i> , 2011 , 333, 850-6	33.3	891
23	Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. <i>Journal of Infectious Diseases</i> , 2010 , 201, 946-55	7	79
22	Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. <i>PLoS Pathogens</i> , 2010 , 6, e1001195	7.6	67
21	Clonal dissection of the human memory B-cell repertoire following infection and vaccination. <i>European Journal of Immunology</i> , 2009 , 39, 1260-70	6.1	149
20	Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. <i>Journal of Virology</i> , 2008 , 82, 3220-35	6.6	128
19	Human monoclonal antibodies by immortalization of memory B cells. <i>Current Opinion in Biotechnology</i> , 2007 , 18, 523-8	11.4	62
18	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> ,	50.4	44
17	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies		10
16	SARS-CoV-2 Omicron spike mediated immune escape and tropism shift		23
15	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement		11

14	Defective neutralizing antibody response to SARS-CoV-2 in vaccinated dialysis patients	2
13	Structure, receptor recognition and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein	2
12	The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity	53
11	Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70	106
10	Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells	129-139
9	The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2	72
8	Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies	18
7	SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough	62
6	A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery	13
5	Predicting the mutational drivers of future SARS-CoV-2 variants of concern	6
4	Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution	6
3	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains	3
2	ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies	3
1	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages	5